Boehringer Ingelheim:
a) March 2012 Stephen Klaschka appointed as Director of Innovation Management & Strategy at BI. To be stationed in USA.
b) BI Headquarters in Germany. BI Pharmaceutical giant.
c) Decade of consistent growth that outpaced the industry.
d) 2010 expiry of patent protection. Revenues dropped by US$ 1.4 billion.
e) Company striving for creation of Innovation mindset across all levels of organization.
f) Klaschka’s mandate was threefold:
i) Create internal network, ii) Establish internal structures, processes, norms and values. iii) Leverage employee suggestions.
g) To accomplish this mandate he was given a free hand, but was held accountable for results.
h) Klaschka had also to launch BI school of Intrapreneurs.
i) Challenges faced by SK,
i) How to change DNA of BI. ii) How to develop framework for innovation and institutionalize it. iii) How devise matrix to asses own value addition.
j) SK Bio
i) Mid 70’s Early schooling. ii) Graduated in 1986 in computer sciences. iii) Developed process management software for his parents dermatology clinic. iv) Then started his own software and IT related business.
v) 1st took up job as programmer in medical informatics department. Worked for 6 years while running his own business along side. vi) KS developed proprietary software’s and sold it to firms for a fee and billed them later for updates. vii) 1984 joined Schering as software developer. He automated the clinical trial databases and regulatory compliance reporting systems, which expedited the market approval of drugs like Yaz and godovist. viii) 1999 moved to BI.